RT Journal Article SR Electronic T1 Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia JF Saudi Medical Journal JO Saudi Med J FD Prince Sultan Military Medical City SP 697 OP 704 DO 10.15537/smj.2018.7.22146 VO 39 IS 7 A1 Saud Al Sifri A1 Owayed Al Shammeri A1 Saleh Al Jaser A1 Abdullah Alkhenizan A1 Atif Bin Shafi Shafiurrehman A1 Bassem Morcos A1 Sameh Wajih A1 Ibrahim Elnahal A1 Martin Horack A1 Philippe Brudi A1 Dominik Lautsch A1 Baishali Ambegaonkar A1 Ami Vyas A1 Carl A. Baxter A1 Anselm K. Gitt YR 2018 UL http://smj.org.sa/content/39/7/697.abstract AB Objectives: To provide an overview of the extent of hyperlipidemia in very high-risk patients, and how lipid-lowering therapy (LLT) is used in a real-world setting.Methods: In this multicenter observational study, data were collected from LLT-treated patients with stable CHD or an ACS in Saudi Arabia between 2013 and 2014. Individuals were included if they were >18 years and had a full lipid profile available, recorded either prior to the baseline physician visit (CHD patients) or within 24-hours of admission to hospital (ACS patients).Results: A total of 737 patients were included in the study, 597 with stable CHD and 140 with ACS. Few patients in either group had an LDL-C level of <70 mg/dl, which is advocated for very high-risk patients (24.3% and 11.4%, respectively). The median distances to this value were 19.0 mg/dl (CHD) and 25.0 mg/dl (ACS). Low doses of statins were being utilized (31 and 24 mg/day for CHD and ACS, respectively), with only minimal intensification for the ACS patients after hospital admission (41 mg/day at follow-up).Conclusions: Achievement of recommended LDL-C levels was poor for patients with stable CHD or an ACS. Statin intensity was low, indicating huge scope for intensifying the treatment of these very high-risk patients.